To the full analysis
Artivion stock: growth
AORTArtivion reported $441.33M in revenue for fiscal 2025, up 13.6% on the prior year, up 11.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.3%
per year from 2006 to 2025, per share 5.9%
Earnings (Annual rate)
18.9%
per year from 2006 to 2025
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.8% | 11.7% | 9.3% |
| Revenue per share | 7.8% | 6.4% | 5.9% |
| Earnings | no data | 9.3% | 18.9% |
| Earnings per share | no data | 4.6% | no data |
| Free cash flow | −30.1% | −19.5% | no data |
| Free cash flow per share | −32.6% | −23.4% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $81.31M | $365K | −$2.71M |
| 2007 | $94.76M | $7.2M | $8.09M |
| 2008 | $105.06M | $32.91M | $7.8M |
| 2009 | $111.69M | $8.68M | $14.88M |
| 2010 | $116.65M | $3.94M | $13.31M |
| 2011 | $119.63M | $7.37M | $14.21M |
| 2012 | $131.72M | $7.95M | $15.92M |
| 2013 | $140.76M | $16.17M | $12.43M |
| 2014 | $144.64M | $7.32M | $2.8M |
| 2015 | $145.9M | $4.01M | $7.34M |
| 2016 | $180.38M | $10.78M | $12.3M |
| 2017 | $189.7M | $3.7M | $3.76M |
| 2018 | $262.84M | −$3.81M | $4.1M |
| 2019 | $276.22M | $1.72M | $7.76M |
| 2020 | $253.23M | −$16.68M | $5.04M |
| 2021 | $298.84M | −$14.83M | −$15.68M |
| 2022 | $313.79M | −$19.19M | −$15.87M |
| 2023 | $354M | −$30.69M | $11.4M |
| 2024 | $388.54M | −$13.36M | $11.05M |
| 2025 | $441.33M | $9.77M | $839K |
Revenue by segment
How Artivion, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Aortic Stent Grafts36%
- On X23%
- Preservation Services22%
- Surgical Sealants17%
- Other2%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Aortic Stent Grafts | $85.39M | $92.75M | $107.47M | $123.08M | $159.37M | 36.1% |
| On X | $57.36M | $63.9M | $74.53M | $83.98M | $101.74M | 23.1% |
| Preservation Services | $77.24M | $83.44M | $92.82M | $98.31M | $95.51M | 21.6% |
| Surgical Sealants | $70.71M | $65.38M | $68.02M | $73.9M | $76.6M | 17.4% |
| Other | $8.13M | $8.32M | $11.17M | $9.27M | $8.11M | 1.8% |
| Total revenue | $298.84M | $313.79M | $354M | $388.54M | $441.33M | 100% |
Revenue by region
Where Artivion, Inc. generates its revenue.
- North America50%
- Europe, the Middle East, and Africa34%
- Asia Pacific10%
- Latin America5%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| North America | $197.94M | $221.74M | 50.2% |
| Europe, the Middle East, and Africa | $131.52M | $151.37M | 34.3% |
| Asia Pacific | $37.2M | $44.25M | 10% |
| Latin America | $21.88M | $23.97M | 5.4% |
| Total revenue | $388.54M | $441.33M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 21 Feb 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.